Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)

13. august 2026 opdateret af: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of 611 (Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Children (2 Years Old ≤ Age < 12 Years Old) With Moderate to Severe Atopic Dermatitis (AD)

This study is a 2-part (parts A and B) study.The primary objective of the study is to evaluate the efficacy of 611 in Chinese Children with moderate to severe atopic dermatitis (AD).

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study comprises Part A and Part B. Part A is a PK study in pediatric participants aged ≥2 years to <6 years with moderate to severe AD; Part B is a Phase III confirmatory trial for pediatric participants aged ≥2 years to <12 years with moderate to severe AD.

The maximum study duration for part A is 30 weeks per participants, including a screening period of up to 6 weeks, a 18-week treatment period, and an 6-week follow-up period.

The maximum study duration for part B is 60 weeks per participants, including a screening period of up to 6 weeks, a 18-week Double blind treatment period, a 36-week maintenance treatment period, and an 6-week follow-up period.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

246

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

  • Kina
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100045
        • Beijing Children's Hospital, Capital Medical University
        • Ledende efterforsker:
          • Lin Ma
        • Ledende efterforsker:
          • Zigang Xu
        • Kontakt:
      • Beijing, Beijing Municipality, Kina, 100050
        • Beijing Friendship hospital, Capital Medical University
        • Ledende efterforsker:
          • Fenglin Zhuo
        • Kontakt:
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510091
        • Dermatology Hospital, Southern Medical University
        • Kontakt:
        • Ledende efterforsker:
          • zhimiao Lin
        • Ledende efterforsker:
          • Xiaoping Pei
    • Hunan
      • Changsha, Hunan, Kina, 410007
        • Hunan Children's Hospital
        • Ledende efterforsker:
          • Zhu Wei
        • Kontakt:
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310003
        • Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
        • Ledende efterforsker:
          • Liming Wu
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. The participants and their legally acceptable representatives are able to understand and comply with the research procedures, agree to participate in the research, and sign the Informed Consent Form (ICF) ;
  2. When signing the informed consent form, the age should be ≥ 2 years old and < 6 years old for part A, and ≥ 2 years old and < 12 years old for part B. any gender, with body weight ≥ 15 kg at baseline;
  3. During the screening process, patients were diagnosed with atopic dermatitis (AD) according to the Hanifin - Rajka criteria, and their AD medical history was evaluated by researchers to be ≥ 6 months for participants aged ≥2 years to <6 years, ≥ 3 months for participants aged ≥6 years to <12 years;
  4. At the screening and baseline, the Eczema Area and Severity Index (EASI) score is ≥ 16 points;
  5. At the screening and baseline, the Investigator Global Assessment (IGA) score is ≥3 points;
  6. At the time of screening and baseline, the affected body surface area (BSA) by atopic dermatitis (AD) is ≥10%;
  7. At baseline, the weekly average score of Daily pruritus Numerical Rating Scale (NRS) is ≥ 4 points;
  8. Participants should have relevant medical records, other medical visit records, or other evidence within the previous year for researchers to evaluate. The participants have poor efficacy of topical drug treatment;
  9. Be willing to use a stable dose of emollient (moisturizer) on the affected areas of atopic dermatitis (AD) twice a day for at least 7 days before randomization and continue to use it throughout the study period;
  10. Participants with potential fertility (e.g., females who have experienced menarche or males who have had nocturnal emissions) must agree to avoid sexual activity or use highly effective contraceptive methods throughout the entire study period and for at least 3 months after the last dose of the medication;
  11. The participants (if applicable) and their legally acceptable representatives shall be able to understand and complete (either independently or with the assistance of a guardian) the research - related questionnaire filling.

Exclusion Criteria:

  1. Intolerance to TCS / TCI treatment or contraindications to TCS / TCI;
  2. Merge other skin comorbidities that may interfere with the research evaluation;
  3. Combined with active parasitic infections (such as helminths) or suspected parasitic infections ;
  4. Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC) ;
  5. Randomly select patients with any malignant tumor diagnosed within the past 5 years or currently having the disease;
  6. The participant had a severe infection requiring intravenous antibiotics and/or hospitalization within 4 weeks before randomization, or had an active infection requiring oral antibiotics within 2 weeks before randomization, and the investigator evaluated that there might be uncontrollable risks for the participant to participate in this study. Or with a skin infection that requires treatment with topical anti-infective agents within 1 week before randomization;
  7. A history of known or suspected immunosuppression, including a history of invasive opportunistic infections; or those who, although the infection has resolved, are considered by the investigator to be likely to have frequent recurrences;
  8. Active tuberculosis, unless that was well documented that the participants had adequately treated;
  9. Any medical condition that, in the opinion of the investigator, is serious or unstable and may affect the safety of the participants during the study and/or prevent the participants from completing the study, including but not limited to cardiovascular, gastrointestinal, liver, kidney, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, and mental diseases;
  10. Participants who have received topical therapies for AD systemic traditional Chinese medicine for AD, systemic glucocorticoids, or other immunosuppressants / immunomodulators, any cell-depleting agents, monoclonal antibodies within a specified period prior to randomization.
  11. Received live vaccines or live attenuated vaccines within 4 weeks before randomization;
  12. Participants with abnormal laboratory parameters deemed ineligible for enrollment at the Investigator's discretion. ;
  13. At the screening, the test results are positive for hepatitis B, positive for hepatitis C virus antibody (HCVAb), positive for human immunodeficiency virus antibody (HIVAb), and positive for serum Treponema pallidum antibody (TPAb);
  14. Used any investigational drugs within 8 weeks or 5 half-lives (whichever is longer) before randomization;
  15. Had a history of alcohol or drug abuse within 6 months before randomization;
  16. Known to be allergic or intolerant to any components of the investigational drug;
  17. Planned or were expected to undergo major surgical operations during the study period;
  18. According to the investigator's judgment, the participants were not suitable to participate in the study due to other diseases or reasons.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Part A (Open-label PK study)
Age cohort :≥2 years old to <6 years old
Medicin: 611
Solution for injection, subcutaneous (SC)
Eksperimentel: Part B (Double-blind confirmatory study) 611
The results of part A will be used to guide the enrollment for participants aged ≥2 years to <6 years with AD for part B.
Medicin: 611
Solution for injection, subcutaneous (SC)
Placebo komparator: Part B (Double-blind confirmatory study) placebo
Medicin: Matchende placebo
Injektionsvæske, opløsning, subkutan (SC)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Part A: drug concentration.
Tidsramme: Baseline, Week 24.
concentration of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) .
Baseline, Week 24.
Part B: Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Improvement in Score From Baseline) at Week 18.
Tidsramme: Baseline, Week 18.
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Baseline, Week 18.
Part B: Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Improvement From Baseline of Greater Than or Equal to (>=) 2 Points From Baseline to Week 18.
Tidsramme: Baseline to Week 18.
The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.
Baseline to Week 18.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Part A: Adverse events (AEs), measurement of vital signs, physical examination, electrocardiogram and laboratory tests at each visit.
Tidsramme: Baseline, Week 24.
The incidence and severity of treatment emergent adverse event (TEAE), including Serious Adverse Event (SAE), as well as clinical symptoms, and any abnormalities of vital signs, physical examinations, electrocardiogram, laboratory tests and, etc.
Baseline, Week 24.
Part A: Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Improvement in Score From Baseline) at each efficacy evaluation visit point.
Tidsramme: Baseline, Week 24.
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Baseline, Week 24.
Part A: Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Improvement From Baseline of Greater Than or Equal to (>=) 2 Points From Baseline to each efficacy evaluation visit point.
Tidsramme: Baseline to Week24.
The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.
Baseline to Week24.
Part A: Number of Participants With EASI-50 (>=50% Improvement From Baseline).
Tidsramme: Baseline, Week 24.
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Baseline, Week 24.
Part A: Number of Participants With EASI-90 (>=90% Improvement From Baseline).
Tidsramme: Baseline, Week 24.
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Baseline, Week 24.
Part A: Number of Participants Who Achieved >=4 Points Points With Improvement From Baseline in Weekly Average of Daily pruritus Numerical Rating Scale (NRS) Score From Baseline.
Tidsramme: Baseline to Week 24.
pruritus Numerical Rating Scale (NRS) is an assessment tool used to report the intensity of a participant's pruritus(itch), during a 24-hour recall period. Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]), higher scores indicated greater severity.
Baseline to Week 24.
Part A: Percentage of Participants With Anti-drug Antibodies and Neutralizing Antibodies.
Tidsramme: Baseline to Week 24.
Immunogenicity assessment will be based on Anti-drug Antibodies (ADAs) response and development of Neutralizing Antibodies (NABs). Percentage is calculated based on the number of evaluable participants and calculated by number of participants with treatment-emergent positive anti-drug antibodies / number of evaluable participants * 100%.
Baseline to Week 24.
Part A: Change in serum concentrations of Thymus and activation regulated chemokine (TARC), IgE, lactate dehydrogenase (LDH) , Change in whole blood eosinophil counts.
Tidsramme: Baseline to Week 24.
Change in serum concentrations of TARC, IgE, LDH , Change in whole blood eosinophil counts.
Baseline to Week 24.
Part B: Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Improvement in Score From Baseline) at each efficacy evaluation visit point except for Week 18.
Tidsramme: Baseline, Week 60.
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Baseline, Week 60.
Part B: Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Improvement From Baseline of Greater Than or Equal to (>=) 2 Points From Baseline to each efficacy evaluation visit point except for Week 18.
Tidsramme: Baseline to Week 60.
The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.
Baseline to Week 60.
Part B: Number of Participants With EASI-50 (>=50% Improvement From Baseline) .
Tidsramme: Baseline, Week 60.
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Baseline, Week 60.
Part B: Number of Participants With EASI-90 (>=90% Improvement From Baseline).
Tidsramme: Baseline, Week 60.
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Baseline, Week 60.
Part B: Number of Participants Who Achieved >=4 Points Points With Improvement From Baseline in Weekly Average of Daily pruritus Numerical Rating Scale (NRS) From Baseline.
Tidsramme: Baseline to Week 60.
pruritus Numerical Rating Scale (NRS) is an assessment tool used to report the intensity of a participant's pruritus(itch), during a 24-hour recall period. Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]), higher scores indicated greater severity.
Baseline to Week 60.
Part B: Topical Corticosteroid (TCS) Medication-free Days From Baseline to Week 18.
Tidsramme: Baseline to Week 18.
TCS medication-free days is calculated as the number of days that a participant used neither TCS nor system rescue therapy divided by the study days of each period.
Baseline to Week 18.
Part B:Adverse events (AEs), measurement of vital signs, physical examination, electrocardiogram and laboratory tests at each visit.
Tidsramme: Up to 60 Weeks.
The incidence and severity of treatment emergent adverse event (TEAE), including Serious Adverse Event (SAE), as well as clinical symptoms, and any abnormalities of vital signs, physical examinations, electrocardiogram, laboratory tests and, etc.
Up to 60 Weeks.

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Part B: drug concentration.
Tidsramme: Baseline to Week 60.
concentration of 611.
Baseline to Week 60.
Part B: Percentage of Participants With Anti-drug Antibodies and Neutralizing Antibodies.
Tidsramme: Baseline to Week 60.
Immunogenicity assessment will be based on Anti-drug Antibodies (ADAs) response and development of Neutralizing Antibodies (NABs). Percentage is calculated based on the number of evaluable participants and calculated by number of participants with treatment-emergent positive anti-drug antibodies / number of evaluable participants * 100%.
Baseline to Week 60.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Efterforskere

  • Ledende efterforsker: Lin Ma, Doctor, Beijing Children's Hospital
  • Ledende efterforsker: ZiGang Xu, Doctor, Beijing Children's Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. september 2026

Primær færdiggørelse (Anslået)

1. september 2027

Studieafslutning (Anslået)

1. juli 2028

Datoer for studieregistrering

Først indsendt

7. august 2026

Først indsendt, der opfyldte QC-kriterier

13. august 2026

Først opslået (Faktiske)

17. august 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. august 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • SSGJ-611-PED-AD-III-02

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner